Dawson James Securities launched coverage of Dyadic International (NASDAQ:DYAI) with a “buy” rating and $14 price target. The stock closed at $6.66 on Oct. 15. Dyadic has been developing a gene expression platform over...
The common stock of Dyadic International (OTCQX:DYAI) was approved for listing on The Nasdaq Capital Market, beginning on April 17, under the trading symbol, DYAI. “Our listing on the NASDAQ is a major milestone...
Noble Capital Markets initiated coverage of Dyadic International (OTC:DYAI) with an “outperform” rating and price target of $4. The stock closed at $1.96 on Jan. 9. Over the past two decades, Dyadic has developed an...